Fig. 5

Selective targeting of CXCR2 reduces tumor growth in LL2 orthotopic lung cancer and subcutaneous tumor models. a, Therapy regimen of the experiment. CXCR2 inhibitor SB225002 was administered at 10 mg/kg by intraperitoneal (i.p.) injection every day, n = 6–7. b, Tumors from vehicle- and SB225002-treated groups of lung orthotopic model (upper panel) and subcutaneous tumor model (down panel) at the end point of experiment, respectively. c-d, Tumor nodules in the lung and lung weight of the orthotopic model treated with vehicle or SB225002, Data was shown as mean ± SD, n = 5. e-f, Tumor growth curves and tumor weight at the sacrifice of subcutaneous xenograft model. Data was shown as mean ± SD, n = 5. g-h, Body weight changes of the mice from orthotopic model (g) and subcutaneous xenograft model (h). Data was shown as mean ± SD, n = 5. *p < 0.05, **p < 0.01, ***p < 0.001, ns represents p>0.05